Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01056263 · ClinicalTrials.gov registry record
Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 52
- Enrollment target
NCT01056263 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 52 participants.
The verdict
NCT01056263 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 \[NCT00076011\] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.
Interventions
- DRUG axitinib: observational study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01056263
The ClinicalTrials.gov registry entry for NCT01056263 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which axitinib: observational study is the first listed.
NCT01056263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01056263 about?
NCT01056263 is a clinical study titled "Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012". The primary objective of this observational study is to retrospectively collect current survival data for patients originally included in axitinib A4061012 \[NCT00076011\] study to estimate the 5-year survival rate in subjects with metastatic renal cancer cell treated with axitinib.
What is the current status of trial NCT01056263?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2010-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01056263?
The interventions under investigation include: axitinib: observational study (DRUG).
Who is sponsoring clinical trial NCT01056263?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.